Head to Head Comparison: Fresenius SE & Co. (OTCMKTS:FSNUY) vs. U.S. Physical Therapy (NYSE:USPH)

U.S. Physical Therapy (NYSE:USPH) and Fresenius SE & Co. (OTCMKTS:FSNUY) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, dividends, risk, analyst recommendations, earnings and valuation.

Analyst Recommendations

This is a summary of current ratings and price targets for U.S. Physical Therapy and Fresenius SE & Co., as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
U.S. Physical Therapy	0	3	4	0	2.57
Fresenius SE & Co.	0	0	2	0	3.00

U.S. Physical Therapy currently has a consensus price target of $105.33, indicating a potential upside of 32.54%. Given U.S. Physical Therapy’s higher possible upside, equities analysts clearly believe U.S. Physical Therapy is more favorable than Fresenius SE & Co..

Risk and Volatility

U.S. Physical Therapy has a beta of 1.29, suggesting that its stock price is 29% more volatile than the S&P 500. Comparatively, Fresenius SE & Co. has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500.

Valuation and Earnings

This table compares U.S. Physical Therapy and Fresenius SE & Co.”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
U.S. Physical Therapy	$671.34 million	1.80	$31.42 million	$2.38	33.39
Fresenius SE & Co.	$23.63 billion	N/A	$509.67 million	$0.55	26.04

Fresenius SE & Co. has higher revenue and earnings than U.S. Physical Therapy. Fresenius SE & Co. is trading at a lower price-to-earnings ratio than U.S. Physical Therapy, indicating that it is currently the more affordable of the two stocks.

Dividends

U.S. Physical Therapy pays an annual dividend of $1.80 per share and has a dividend yield of 2.3%. Fresenius SE & Co. pays an annual dividend of $0.19 per share and has a dividend yield of 1.3%. U.S. Physical Therapy pays out 75.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Fresenius SE & Co. pays out 34.5% of its earnings in the form of a dividend. U.S. Physical Therapy has increased its dividend for 6 consecutive years. U.S. Physical Therapy is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Profitability

This table compares U.S. Physical Therapy and Fresenius SE & Co.’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
U.S. Physical Therapy	5.71%	8.62%	3.64%
Fresenius SE & Co.	5.26%	9.72%	4.48%

Summary

U.S. Physical Therapy beats Fresenius SE & Co. on 8 of the 14 factors compared between the two stocks.

About U.S. Physical Therapy

U.S. Physical Therapy, Inc. operates outpatient physical therapy clinics. The company operates through Physical Therapy Operations and Industrial Injury Prevention Services segments. The company provides pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. It offers industrial injury prevention services, including onsite injury prevention and rehabilitation, performance optimization, post-offer employment testing, functional capacity evaluations, and ergonomic assessments through physical therapists and specialized certified athletic trainers for Fortune 500 companies, and other clients comprising insurers and their contractors. U.S. Physical Therapy, Inc. was founded in 1990 and is based in Houston, Texas.

About Fresenius SE & Co.

Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, dialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients. This segment offers I.V. generic drugs; biosimilar drugs for autoimmune diseases and oncology; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment provides clinical and nursing care facilities. The Fresenius Vamed segment provides services for hospitals and other healthcare facilities. This segment also offers operational management of healthcare facilities and provides services to patients. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.